Literature DB >> 17316169

Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study.

Kate X Zhong1, P N Tariot, J Mintzer, M C Minkwitz, N A Devine.   

Abstract

In this 10-week, double-blind, fixed-dose study, elderly institutionalized patients with dementia and agitation were randomized (3:3:2) to quetiapine 200mg/day, 100mg/day, or placebo. The primary endpoint was change in Positive and Negative Syndrome Scale (PANSS)-Excitement Component (EC) scores at endpoint, analysed using last observation carried forward (LOCF) and observed cases (OC) approaches. Other efficacy measures were the Clinical Global Impression of Change (CGI-C), and response rates (percentage with > or =40% reduction [PANSS-EC]; "much" or "very much improved" [CGI-C]), Neuropsychiatric Inventory-Nursing Home version (NPI-NH), and Cohen-Mansfield Agitation Inventory (CMAI). The key safety measure was incidence of adverse events; change in Mini-Mental State Examination (MMSE) was also assessed. Baseline characteristics of 333 participants (quetiapine 200mg/day, n=117; quetiapine 100mg/day, n=124; placebo, n=92) and completion rates (63-65%) were comparable among groups. Compared with placebo, quetiapine 200mg/day was associated with clinically greater improvements in PANSS-EC (LOCF, p=0.065; OC, p=0.014 [ANCOVA]), CGI-C (LOCF, p=0.017; OC, p=0.002 [ANOVA]), and CGI-C response rates (LOCF, p=0.002; OC, p<0.001 [Chi-square test]). Quetiapine 100mg/day did not differentiate from placebo on these measures. There were no between-group differences in NPI-NH or CMAI. Incidences of cerebrovascular adverse events, postural hypotension, and falls were similar among groups. MMSE did not change in any group. Mortality was numerically higher in the quetiapine groups; rates were not statistically different from placebo. The results of this study suggest that quetiapine 200mg/day was effective and well-tolerated for treating agitation associated with dementia. However, caution should be exercised given the concerns regarding increased mortality with atypical antipsychotics in this vulnerable patient population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17316169     DOI: 10.2174/156720507779939805

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  40 in total

Review 1.  Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials.

Authors:  Salvatore Gentile
Journal:  Psychopharmacology (Berl)       Date:  2010-07-27       Impact factor: 4.530

2.  Association of quetiapine with ischemic brain stem stroke: a case report and discussion.

Authors:  Selma BozkurtZincir; Betul F Ozdilek; Serkan Zincir
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

Review 3.  Alternatives to atypical antipsychotics for the management of dementia-related agitation.

Authors:  Michael J Passmore; David M Gardner; Yvette Polak; Kiran Rabheru
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 4.  Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

Authors:  Emilio Sacchetti; Cesare Turrina; Paolo Valsecchi
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

5.  Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies.

Authors:  Anna Borisovskaya; Marcella Pascualy; Soo Borson
Journal:  Curr Psychiatry Rep       Date:  2014-09       Impact factor: 5.285

Review 6.  Atypical antipsychotic-induced metabolic disturbances in the elderly.

Authors:  Melanie Dawn Guenette; Araba Chintoh; Gary Remington; Margaret Hahn
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

7.  Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials.

Authors:  Alexander Wolf; Stefan Leucht; Frank-Gerald Pajonk
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-16       Impact factor: 5.270

Review 8.  Pharmacological management of behavioral symptoms associated with dementia.

Authors:  Subramoniam Madhusoodanan; Mark Bryan Ting
Journal:  World J Psychiatry       Date:  2014-12-22

9.  Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.

Authors:  Ling Zheng; Wendy J Mack; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; T Scott Stroup; David L Sultzer; Pierre N Tariot; Cheryl Vigen; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2009-04-15       Impact factor: 18.112

10.  Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.

Authors:  Khachen Kongpakwattana; Ratree Sawangjit; Itthipol Tawankanjanachot; J Simon Bell; Sarah N Hilmer; Nathorn Chaiyakunapruk
Journal:  Br J Clin Pharmacol       Date:  2018-05-14       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.